| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18802150 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 106 journal articles in the PubMed database | Email to a friend | | |
| Paulussen M, Craft AW, Lewis I, et al.
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. [Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
J Clin Oncol 2008 Sep 20; 26(27):4385-93.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Grier HE, Krailo MD, Tarbell NJ, et al.
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
N Engl J Med 2003 Feb 20; 348(8):694-701.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Paulussen M, Ahrens S, Dunst J, et al.
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. [Journal Article, Multicenter Study]
J Clin Oncol 2001 Mar 15; 19(6):1818-29.
Abstract | Full Citation | Find Related Articles | | Miser JS, Krailo MD, Tarbell NJ, et al.
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. [Clinical Trial, Journal Article, Randomized Controlled Trial]
J Clin Oncol 2004 Jul 15; 22(14):2873-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Bacci G, Picci P, Ferrari S, et al.
Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies. [Clinical Trial, Journal Article]
Cancer 1998 Mar 15; 82(6):1174-83.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Yock TI, Krailo M, Fryer CJ, et al.
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. [Journal Article, Randomized Controlled Trial]
J Clin Oncol 2006 Aug 20; 24(24):3838-43.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Bacci G, Picci P, Ruggieri P, et al.
No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies. [Clinical Trial, Journal Article]
J Chemother 1993 Aug; 5(4):247-57.
Abstract | Full Citation | Find Related Articles | | Ferrari S, Mercuri M, Rosito P, et al.
Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. [Clinical Trial, Journal Article]
J Chemother 1998 Dec; 10(6):484-91.
Abstract | Full Citation | Find Related Articles | | Kolb EA, Kushner BH, Gorlick R, et al.
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
J Clin Oncol 2003 Sep 15; 21(18):3423-30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
